ArticleMicroorganisms2026
A Case Report of Valacyclovir-Associated Neurotoxicity.
Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 69-year-old Hispanic female with end-stage renal disease (ESRD) on hemodialysis and a complex medical history who presented with acute altered mental status shortly after initiating valacyclovir at a non-renally adjusted dose. The patient was admitted to inpatient services and treated with a presumptive diagnosis of valacyclovir-associated neurotoxicity (VAN). The patient received hemodialysis for three consecutive days, resulting in neurologic improvement. Additional competing causes of altered mental status and encephalopathy were investigated and ruled out over the course of a five-day hospitalization. The patient was subsequently discharged with a diagnosis of VAN. This case underscores the importance of proper renal dose adjustment and medication safety in patients with ESRD to prevent serious, avoidable adverse drug events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.